<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>[1-(2,3-dihydro-1H-inden-1-yl)ethyl](prop-2-yn-1-yl)amine | Nervorum Biotechnologies Inc.</title>
  <link rel="stylesheet" href="style.css">
  <style>
    :root {
      --bg-dark: #0f0f0f;
      --bg-mid: #1c1c1c;
      --bg-light: #1c1c1c;
      --text-light: #ffffff;
      --accent: #00ccff;
    }

    * { margin: 0; padding: 0; box-sizing: border-box; }
    body {
      font-family: 'Montserrat', sans-serif;
      background: var(--bg-dark);
      color: var(--text-light);
      line-height: 1.5;
    }
    a { color: var(--accent); text-decoration: none; }

    header {
      background: var(--bg-mid);
      display: flex;
      justify-content: space-between;
      align-items: center;
      padding: 1.5rem 3rem;
      position: sticky;
      top: 0;
      z-index: 100;
    }
    header h1 { font-size: 1.5rem; font-weight: 700; color: var(--text-light); }
    nav a {
      margin-left: 2rem;
      font-weight: 500;
      color: var(--text-light);
      transition: color 0.3s;
    }
    nav a:hover { color: var(--accent); }

    .hero {
      text-align: center;
      padding: 6rem 1rem 4rem 1rem;
      background: linear-gradient(180deg, #111111 0%, #1a1a1a 100%);
    }
    .hero h2 {
      font-size: 2.5rem;
      font-weight: 700;
      margin-bottom: 1rem;
      color: var(--text-light);
    }
    .hero p {
      font-size: 1.2rem;
      opacity: 0.9;
      max-width: 700px;
      margin: 0 auto;
      color: var(--text-light);
    }
    .hero img {
      max-width: 400px;
      width: 100%;
      margin-top: 2rem;
      border-radius: 10px;
      box-shadow: 0 10px 30px rgba(0,0,0,0.7);
    }

    .container { max-width: 1000px; margin: 3rem auto; padding: 0 1rem; }

    section {
      background: var(--bg-light);
      color: var(--text-light);
      padding: 2rem;
      border-radius: 12px;
      margin-bottom: 2rem;
      box-shadow: 0 6px 20px rgba(0,0,0,0.2);
    }
    section h2 {
      font-size: 1.8rem;
      margin-bottom: 1rem;
      border-bottom: 2px solid var(--accent);
      padding-bottom: 0.5rem;
      color: var(--text-light);
    }

    .info-list { display: grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr)); gap: 1rem; }
    .info-list div {
      background: var(--bg-mid);
      padding: 1rem;
      border-radius: 8px;
      box-shadow: 0 4px 10px rgba(0,0,0,0.3);
    }
    .info-list div h3 { font-size: 1rem; color: var(--accent); margin-bottom: 0.3rem; }
    .info-list div p { font-size: 0.95rem; color: var(--text-light); }

    footer {
      background: var(--bg-mid);
      color: var(--text-light);
      text-align: center;
      padding: 2rem 1rem;
      margin-top: 4rem;
    }
    footer a { color: var(--accent); }

    @media (max-width: 768px) {
      header { flex-direction: column; text-align: center; gap: 1rem; }
      .hero h2 { font-size: 2rem; }
    }
  </style>
</head>
<body>

  <section class="animated-background">
    <div id="stars1"></div>
    <div id="stars2"></div>
    <div id="stars3"></div>
  </section>

  <header>
    <h1>Nervorum Biotechnologies Inc.</h1>
    <nav>
      <a href="https://nervorum.com">Home</a>
      <a href="https://nervorum.com/findings">Findings</a>
    </nav>
  </header>

  <section class="hero">
    <h2>Indalarium</h2>
    <p>A novel indanyl-propargylamine featuring an indane core with an N-propargyl substituent. This compound shows strong potential as a CNS-active MAO inhibitor with favorable physicochemical and pharmacokinetic properties.</p>
    <img src="Indalarium.png" alt="Molecule Structure">
  </section>

  <div class="container">
    <section>
      <h2>Overview & Identification</h2>
      <div class="info-list">
        <div>
          <h3>IUPAC</h3>
          <p>[1-(2,3-dihydro-1H-inden-1-yl)ethyl](prop-2-yn-1-yl)amine</p>
        </div>
        <div>
          <h3>Formula</h3>
          <p>C14H17N</p>
        </div>
        <div>
          <h3>Molecular Weight</h3>
          <p>199.30 g/mol</p>
        </div>
        <div>
          <h3>Exact Molecular Weight</h3>
          <p>199.1361</p>
        </div>
        <div>
          <h3>Composition</h3>
          <p>C: 84.37%, H: 8.60%, N: 7.03%</p>
        </div>
        <div>
          <h3>CAS Number</h3>
          <p>Not assigned (novel compound)</p>
        </div>
      </div>
    </section>

    <section>
      <h2>Physical & Chemical Properties</h2>
      <div class="info-list">
        <div><h3>Intrinsic Solubility (logS)</h3><p>-3.13</p></div>
        <div><h3>logP</h3><p>2.88</p></div>
        <div><h3>logD (pH 7.4)</h3><p>1.08</p></div>
        <div><h3>Most Basic pKa</h3><p>9.21</p></div>
        <div><h3>Hydrogen Bond Donors</h3><p>1</p></div>
        <div><h3>Hydrogen Bond Acceptors</h3><p>1</p></div>
        <div><h3>Rotatable Bonds</h3><p>4</p></div>
        <div><h3>Topological Polar Surface Area (TPSA)</h3><p>≈ 12 Å²</p></div>
        <div><h3>SMILES</h3><p>CC(C1c2ccccc2CC1)NCC#C</p></div>
      </div>
    </section>

    <section>
      <h2>pH-Dependent Properties</h2>
      <h3>Solubility (Log S)</h3>
      <img src="solubility.png" style="width:900px;height:auto;">
      <h3>Lipophilicity (Log D)</h3>
      <img src="lipophilic.png" style="width:900px;height:auto;">
      <p>Predicted solubility and lipophilicity profiles suggest balanced amphiphilicity—low aqueous solubility but suitable membrane permeability for CNS penetration.</p>
    </section>

    <section>
      <h2>Synthesis Overview</h2>
      <div class="info-list">
        <div>
          <h3>Method 1</h3>
          <p>Reductive amination of 1-(2,3-dihydro-1H-inden-1-yl)ethanone with propargylamine, followed by reduction with NaBH₃CN.</p>
        </div>
        <div>
          <h3>Method 2</h3>
          <p>Reaction of 1-(2,3-dihydro-1H-inden-1-yl)ethan-1-amine with propargyl bromide in the presence of base (e.g. Na₂CO₃) in acetonitrile.</p>
        </div>
      </div>
    </section>

    <section>
      <h2>Applications & Uses</h2>
      <div class="info-list">
        <div>
          <h3>Research Use</h3>
          <p>MAO inhibition studies, neuroprotective agent screening, and CNS pharmacokinetics research.</p>
        </div>
        <div>
          <h3>Therapeutic Potential</h3>
          <p>Investigational use for Parkinson’s disease, depression, ADHD, and related neuropsychiatric disorders.</p>
        </div>
        <div>
          <h3>Pharmaceutical Utility</h3>
          <p>Prototype scaffold for propargylamine-based MAO inhibitors; potential salt forms include HCl, mesylate, and fumarate.</p>
        </div>
      </div>
    </section>

    <section>
      <h2>References</h2>
      <ul>
               <li><a href="https://zenodo.org/records/17295081"> </a>Indalarium Patent Draft (Nervorum Biotechnologies Inc., 2025)</li>
        <li>Rasagiline and Selegiline analog structure–activity relationship (SAR) literature</li>
      </ul>
    </section>
  </div>

  <footer>
    &copy; 2025 Nervorum Biotechnologies Inc. | <a href="mailto:info@nervorum.com">Contact</a>
  </footer>

</body>
</html>
